Companies /Healthcare

Cytokinetics Inc

NASDAQ: CYTK Biotechnology
$71.40
▲ $0.49 (+0.69%) today
Markets closed · 7:54pm ET

Q3 2025 Earnings

Reported Nov 5, 2025, 4:00pm ET · SEC source
$-2.55
Miss −56.33%
EPS · est. $-1.63
$1.9M
Miss −69.88%
Revenue · est. $6.4M
+0.3%
Beating market
CYTK vs S&P since report
1 quarter
Consecutive EPS beats

Market Reaction

% change · around the report
0+2%Nov 5Nov 6report 4:00pm ETearnings−0.9%+1.7%
0+2%Nov 5Nov 6earnings−0.9%+1.7%
CYTK +1.7%S&P 500 −0.9%
−2%0+2%Nov 5Nov 6report 4:00pm ETearnings−1.7%+1.7%
−2%0+2%Nov 5Nov 6earnings−1.7%+1.7%
CYTK +1.7%NASDAQ −1.7%
0+5%+10%Nov 4Nov 13report 4:00pm ETearnings−0.8%+10.5%
0+5%+10%Nov 4Nov 13earnings−0.8%+10.5%
CYTK +10.5%S&P 500 −0.8%
−5%0+5%+10%Nov 4Nov 13report 4:00pm ETearnings−2.4%+10.5%
−5%0+5%+10%Nov 4Nov 13earnings−2.4%+10.5%
CYTK +10.5%NASDAQ −2.4%
+1.88%
Day of report
−0.23%
Next session
+8.66%
One week
+2.16%
30 days

S&P 500 over the same 30 days: +1.90%.

Did CYTK Beat Earnings? Q3 2025 Results

Cytokinetics delivered a bruising third quarter, missing on both the top and bottom lines as pre-launch spending and a sizable debt restructuring overwhelmed results. The South San Francisco-based cardiac muscle company posted a loss of $2.55 per share, falling 56.33% short of the consensus estimate of $1.63, while revenue of $1.94 million, composed entirely of collaboration income, came in 69.88% below expectations despite representing 318.1% growth year over year. The primary culprit behind the widening net loss of $306.18 million was a $121.25 million non-cash expense tied to the exchange of roughly $399.50 million in 2027 convertible notes, a restructuring designed to strengthen the balance sheet ahead of aficamten's December 26, 2025 PDUFA date. The company simultaneously raised $750.00 million in new convertible notes, pushing cash and investments to approximately $1.25 billion. Looking ahead, management narrowed full-year GAAP operating expense guidance to $680 million to $700 million, signaling continued heavy investment in commercial readiness as the potential aficamten launch approaches.

Key Takeaways
  • Revenue primarily from collaboration revenues of $1.9 million in Q3 2025
  • R&D expense increase driven by advancing clinical trials and higher personnel-related costs
  • G&A expense increase driven by commercial readiness investments and higher personnel costs
  • Net loss significantly impacted by $121.2 million debt conversion expense from exchange of 2027 Notes

“I'm pleased that our teams continue to demonstrate strong execution and sustained momentum as we approach the PDUFA date for the aficamten NDA. Our commercial preparations have been deliberate and strategic, positioning us well for this milestone.”

Cytokinetics CEO, on the earnings call

Forward Guidance & Outlook

Cytokinetics updated its full-year 2025 financial guidance, narrowing GAAP operating expense (R&D and SG&A) to $680 million to $700 million (from prior $670 million to $710 million), with non-cash stock-based compensation included at $120 million to $110 million, unchanged from prior guidance. The year-over-year increase in operating expense reflects investments toward commercial readiness for aficamten's potential approval and launch. The company expects the FDA PDUFA decision on aficamten by December 26, 2025, a potential EMA decision in 1H 2026, ACACIA-HCM primary cohort topline results in Q2 2026, and continued enrollment across multiple clinical trials through 2026.

CYTK YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$-3,000,000,000$-2,000,000,000$-1,000,000,000$0$463,003$1.9MRevenue$-204,431,776$-166,755,000Operating Income$-3,295,780,409$-306,178,000Net Income
$-3,000,000,000$-2,000,000,000$-1,000,000,000$0RevenueOperating IncomeNet Income

CYTK Revenue by Segment

Net Product Revenue (MYQORZO)
License and Milestone Revenues
Collaboration Revenues

Figures from SEC filings and company reports. Not investment advice.